✦ LIBER ✦

Oral yeast carriage in HIV-infected and non-infected populations in Rosario, Argentina

✍ Scribed by A. G. Luque; M. S. Biasoli; M. E. Tosello; A. Binolfi; S. Lupo; H. M. Magaró

Book ID: 108914571
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 74 KB
Volume: 52
Category: Article
ISSN: 0933-7407
DOI: 10.1111/j.1439-0507.2008.01542.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Carriage of Candida species in oral cavi

Carriage of Candida species in oral cavities of HIV infected patients in South India

✍ C. P. Girish Kumar; Thangam Menon; S. Rajasekaran; B. Sekar; D. Prabu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

Oral manifestations in HIV-infected indi

Oral manifestations in HIV-infected individuals from Thailand and Cambodia

✍ P. A. Reichart; P. Khongkhunthian; C. Bendick 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 161 KB

Clostridium DifficileInfection in Non–HI

Clostridium DifficileInfection in Non–HIV-Immunocompromised Patients and in HIV-Infected Patients

✍ Daniel L. Raines; Fred A. Lopez 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 202 KB

Oral manifestations in HIV infection: fu

Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma

✍ Peter A. Reichart 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 244 KB

Risk indicators for oral candidiasis and

Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults

✍ Amit Chattopadhyay; Daniel J. Caplan; Gary D. Slade; Diane C. Shugars; Hsaio-Chu 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

Phase I trial with oral oxihumate in HIV

Phase I trial with oral oxihumate in HIV-infected patients

✍ Mariëtte E. Botes; J. Dekker; C.E.J. van Rensburg 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

## Abstract Oxihumate is formed through conversion of bituminous coal by controlled wet oxidation. The objective of the study, based on in vitro studies, was to evaluate the safety and toxicity profile of oxihumate at various doses in HIV‐1‐infected individuals. Thirty‐seven antiretroviral‐naïve ad